Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2021-08-16 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
神州细胞独立董事关于公司第一届董事会第十九次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal statement from independent directors providing prior approval opinions on proposals related to a specific financing plan: the issuance of A shares to specific targets in 2021. It references compliance with company law, securities law, and listing rules, and discusses the fairness and reasonableness of the issuance plan. The document is short (1209 characters) and consists mainly of opinions and approvals rather than detailed financial data or full reports. It does not contain comprehensive financial statements or detailed analysis typical of an Annual Report, Interim Report, or Capital/Financing Update. Instead, it is a formal board-related opinion document related to a financing proposal. Given the nature of the content—opinions from independent directors on board meeting matters—and the absence of full financial data, the best fitting category is Board/Management Information (MANG).
2021-08-16 Chinese
北京神州细胞生物技术集团股份公司2021年度向特定对象发行A股股票预案（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled "2021年度向特定对象发行A股股票预案（修订稿）" which translates to "2021 Annual Plan for Private Placement of A Shares (Revised Draft)" by Beijing Sinocelltech Group Limited. It details a plan for a private placement of shares to specific investors, including the background, purpose, issuance details, pricing, number of shares, use of proceeds, lock-up periods, and regulatory approvals required from the China Securities Regulatory Commission (CSRC) and Shanghai Stock Exchange. The document is comprehensive and over 15,000 characters, containing detailed financial and strategic information about the capital raising. This fits the definition of a Capital/Financing Update (CAP), which covers company fundraising and financing activities. It is not an announcement of a report but the actual plan document. Therefore, the correct classification is CAP with high confidence.
2021-08-16 Chinese
北京神州细胞生物技术集团股份公司2021年度向特定对象发行A股股票募集资金使用的可行性分析报告（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "Feasibility Analysis Report on the Use of Funds Raised from the Private Placement of A Shares in 2021" by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It details the company's plan to raise funds through a private placement of shares, specifying the amount to be raised, the intended use of the funds (primarily for new drug R&D projects), and the necessity and feasibility of the investment projects. The document includes detailed descriptions of the projects, investment amounts, and expected impacts on the company's operations and financial status. This type of document is a detailed report analyzing the feasibility and use of capital raised through financing activities, which fits the category of Capital/Financing Update (CAP). It is not an annual or interim report, nor an earnings release or regulatory filing. It is a substantive report on capital raising and fund usage plans, not merely an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2021-08-16 Chinese
神州细胞第一届监事会第十七次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement of resolutions passed at the 17th meeting of the first Supervisory Board of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It details the approval of adjustments to the company's 2021 private placement of A shares, including changes to the fundraising scale and use of proceeds. The document includes voting results and references to related detailed announcements available on the Shanghai Stock Exchange website. The content focuses on decisions made by the supervisory board regarding capital raising plans and related reports, but does not itself contain the full detailed reports or financial statements. The document length is 2931 characters, which is relatively short and consistent with an announcement rather than a full report. It primarily serves as a formal disclosure of board resolutions related to capital raising activities. Therefore, the document fits best into the category of Capital/Financing Update (CAP), as it provides updates on the company's fundraising activities and capital structure changes.
2021-08-16 Chinese
神州细胞第一届董事会第十九次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It details the approval of adjustments to a 2021 private placement of A shares, including changes to the fundraising amount and investment projects. The document includes voting results and references to compliance with relevant laws and regulations. It does not contain financial statements or detailed financial analysis but rather focuses on board decisions related to capital raising and issuance plans. This fits the category of Capital/Financing Update (CAP), as it provides updates on the company's fundraising activities and capital structure changes. The document length is 3184 characters, which is consistent with an announcement rather than a full report. Therefore, the appropriate classification is CAP with high confidence.
2021-08-16 Chinese
关于北京神州细胞生物技术集团股份公司向特定对象发行股票申请文件的第三轮审核问询函的回复报告
Capital/Financing Update Classification · 95% confidence The document is a detailed reply report to a third-round inquiry letter from the Shanghai Stock Exchange regarding a company's application for a private placement of shares (向特定对象发行股票申请文件). It discusses the financing scale, investment projects, adjustments to the issuance plan, detailed clinical research projects, and the rationale for the financing. It includes statements from the issuer, the sponsor (underwriter), and auditors, confirming the authenticity and completeness of the reply. The document is lengthy (over 12,000 characters) and contains substantive content related to capital raising and financing activities, including the use of proceeds and project details. This is not a general regulatory filing or a simple announcement but a detailed response related to a capital raising process. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2021-08-16 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.